Skip to content

Progesterone effect on threatened abortion

To investigate the possible effect of Progesterone Supp on cytokines endocervical concentration of women at risk of abortion

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201012035294N1
Enrollment
100
Registered
2012-03-17
Start date
2006-06-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abortion. Fetus and newborn affected by other maternal complications of pregnancy Spontaneous abortion, fetus

Interventions

Intervention 1: Placebo suppository. Intervention 2: Progesterone suppository 400 mg twice daily for a week.
Placebo
Treatment - Drugs
Progesterone suppository 400 mg twice daily for a week

Sponsors

Vice chancellor for research,Tehran University of Medical Sciences
Lead Sponsor
Vice chancellor for research, Imam Khomeinei Hospital
Collaborator

Eligibility

Sex/Gender
Female
Age
16 Years to 44 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: pregnant women less than 20 weeks of gestation with sign and symptoms of threatened abortion like bleeding, abdominal pain and induction of cervical secretion where included in this study; Exclusion criteria: Lack of satisfaction, hypertension and avoidance of participating in the study were considered as exclusion criteria.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Incidence of abortion. Timepoint: at the end of study. Method of measurement: due to definition, fetal weight less than 500 grams and delivery before 20 weeks.

Secondary

MeasureTime frame
Study the inflammatory cytokines of cervix. Timepoint: before and after treatment. Method of measurement: special kits & Eliza.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Sedigheh Hantoushzadeh

Vali-e-Asr Hospital,Tehran University of Medical Sciences

hantoushzadeh@tums.ac.ir+98 912 127 1209

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026